Profile data is unavailable for this security.
About the company
Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The Company’s platform, DNA-directed RNA interference (ddRNAi), combines ribonucleic acid (RNA) interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is also engaged in developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The Company's BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to permanently silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD) and to simultaneously replace the mutant gene with a wildtype gene (to drive restoration of function in diseased cells).
- Revenue in USD (TTM)7.00k
- Net income in USD-21.69m
- Incorporated2019
- Employees18.00
- LocationBenitec Biopharma Inc3940 Trust WayHAYWARD 94545United StatesUSA
- Phone+1 (510) 780-0819
- Fax+1 (302) 636-5454
- Websitehttps://benitec.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Milestone Pharmaceuticals Inc | 0.00 | -55.09m | 92.94m | 47.00 | -- | 2.33 | -- | -- | -1.25 | -1.25 | 0.00 | 0.7498 | 0.00 | -- | -- | 0.00 | -53.21 | -48.44 | -56.51 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.5592 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Eton Pharmaceuticals Inc | 34.30m | 913.00k | 93.51m | 30.00 | 107.60 | 6.04 | 50.47 | 2.73 | 0.0338 | 0.0338 | 1.33 | 0.6031 | 1.25 | 8.41 | 9.64 | 1,143,467.00 | 3.34 | -46.22 | 5.72 | -58.20 | 66.24 | 72.16 | 2.66 | -76.86 | 1.43 | -- | 0.2447 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
| Nanopharmaceutics Inc | 1.01m | -549.47k | 93.95m | 50.00 | -- | -- | -- | 93.06 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| Oramed Pharmaceuticals, Inc. | 674.00k | 10.46m | 96.29m | 15.00 | 9.53 | 0.5763 | 9.22 | 142.86 | 0.2488 | 0.2488 | 0.0165 | 4.11 | 0.0037 | -- | -- | 44,933.33 | 5.63 | -- | 6.27 | -- | -- | -- | 1,518.25 | -- | -- | -- | 0.162 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
| Athira Pharma Inc | 0.00 | -116.19m | 96.58m | 65.00 | -- | 0.9048 | -- | -- | -3.05 | -3.05 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -63.45 | -30.73 | -72.51 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
| Annovis Bio Inc | 0.00 | -47.53m | 97.75m | 6.00 | -- | -- | -- | -- | -5.04 | -5.04 | 0.00 | -0.3046 | 0.00 | -- | -- | 0.00 | -284.97 | -106.31 | -411.92 | -124.71 | -- | -- | -- | -- | -- | -9.20 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
| Relmada Therapeutics Inc | 0.00 | -94.30m | 97.76m | 20.00 | -- | 1.36 | -- | -- | -3.13 | -3.13 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -85.74 | -- | -95.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| Benitec Biopharma Inc | 7.00k | -21.69m | 98.08m | 18.00 | -- | 2.48 | -- | 14,011.08 | -9.87 | -9.87 | 0.0031 | 4.22 | 0.0006 | -- | 0.1284 | 388.89 | -186.85 | -83.43 | -260.89 | -98.77 | 1,542.86 | 96.86 | -309,885.70 | -468.04 | -- | -307.03 | 0.00 | -- | 2.74 | -53.84 | -7.44 | -- | -56.51 | -- |
| Leap Therapeutics Inc | 0.00 | -53.37m | 98.34m | 54.00 | -- | 1.39 | -- | -- | -2.39 | -2.39 | 0.00 | 1.85 | 0.00 | -- | -- | 0.00 | -64.88 | -80.06 | -74.25 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Assertio Holdings Inc | 142.05m | -332.97m | 98.93m | 53.00 | -- | 0.7355 | -- | 0.6964 | -3.95 | -3.95 | 1.66 | 1.41 | 0.4081 | 1.19 | 3.19 | 2,680,208.00 | -95.65 | -21.51 | -130.77 | -32.05 | 76.96 | 88.68 | -234.40 | -62.10 | 1.45 | -- | 0.2231 | -- | -2.67 | -13.38 | -402.80 | -- | -28.25 | -- |
| SCYNEXIS Inc | 140.39m | 101.33m | 98.98m | 29.00 | 1.30 | 1.34 | -- | 0.7051 | 2.01 | 2.01 | 2.89 | 1.96 | 1.49 | -- | 136.30 | 4,840,862.00 | 107.48 | -30.02 | 175.37 | -36.35 | 88.97 | -- | 72.18 | -86.76 | -- | 193.81 | 0.1433 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| Clearside Biomedical Inc | 8.45m | -34.97m | 99.39m | 30.00 | -- | -- | -- | 11.76 | -0.543 | -0.543 | 0.1321 | -0.2919 | 0.1993 | -- | -- | 281,733.30 | -82.44 | -63.57 | -94.63 | -81.77 | 93.08 | -- | -413.72 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
| Angion Biomedica Corp | 0.00 | -35.19m | 100.88m | 32.00 | -- | 8.33 | -- | -- | -8.81 | -8.81 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -88.05 | -105.91 | -110.32 | -331.69 | -- | -- | -- | -712.81 | -- | -700.88 | 0.00 | -- | -100.00 | -- | 9.31 | -- | -- | -- |
| Beyondspring Inc | 1.75m | -21.03m | 102.65m | 35.00 | -- | -- | -- | 58.62 | -0.5392 | -0.5392 | 0.0449 | -0.6868 | 0.0493 | -- | -- | 48,638.89 | -61.80 | -75.50 | -88.85 | -96.48 | -- | -- | -1,253.46 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
Data as of May 20 2024. Currency figures normalised to Benitec Biopharma Inc's reporting currency: US Dollar USD
29.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Suvretta Capital Management LLCas of 22 Apr 2024 | 1.69m | 18.06% |
| Franklin Advisers, Inc.as of 31 Mar 2024 | 588.31k | 6.28% |
| Janus Henderson Investors US LLCas of 31 Mar 2024 | 244.49k | 2.61% |
| Adage Capital Management LPas of 31 Mar 2024 | 189.19k | 2.02% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 16.70k | 0.18% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 11.80k | 0.13% |
| Geode Capital Management LLCas of 31 Mar 2024 | 10.02k | 0.11% |
| GAMMA Investing LLCas of 31 Mar 2024 | 3.55k | 0.04% |
| Tower Research Capital LLCas of 31 Mar 2024 | 1.75k | 0.02% |
| UBS Securities LLCas of 31 Mar 2024 | 510.00 | 0.01% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
